Business ❯ Pharmaceuticals ❯ Biotechnology

Drug Development

Obesity Treatments Clinical Trials Acquisitions Clinical Research Molecular Glue Degraders Collaboration Bispecific Antibodies RNA Technology Blood Coagulation Treatments Licensing Agreements Efzofitimod Artificial Intelligence Rare Diseases Collaboration Agreements Cystic Fibrosis Treatments Monte Rosa Therapeutics Market Access Evotec SE Regulatory Affairs Prostate Cancer Therapeutics

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Full results will be presented as a late-breaking ASCO GI talk on Jan. 8 ahead of anticipated regulatory evaluation.

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

CSL Secures VarmX Acquisition Option, Funding Phase 3 of Factor Xa Reversal Drug

Vertex Halts VX-993 Acute Pain Program After Phase 2 Trial Failure

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

Pfizer Secures $6 Billion Licensing Deal for Chinese Cancer Drug SSGJ-707